Passage Other Stockholder Equity from 2010 to 2025

PASG Stock  USD 0.38  0.03  7.32%   
Passage Bio's Other Stockholder Equity is increasing over the last several years with slightly volatile swings. Other Stockholder Equity is predicted to flatten to about 550.9 M. During the period from 2010 to 2025 Passage Bio Other Stockholder Equity regressed destribution of quarterly values had coefficient of variationof  124.84 and r-value of  0.87. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2019-12-31
Previous Quarter
719.2 M
Current Value
720.5 M
Quarterly Volatility
168.5 M
 
Covid
Check Passage Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Passage Bio's main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.59. Passage financial statements analysis is a perfect complement when working with Passage Bio Valuation or Volatility modules.
  
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.

Latest Passage Bio's Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Passage Bio over the last few years. It is Passage Bio's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Passage Bio's overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Passage Other Stockholder Equity Regression Statistics

Arithmetic Mean253,974,996
Geometric Mean14,445,306
Coefficient Of Variation124.84
Mean Deviation287,379,244
Median856,000
Standard Deviation317,064,451
Sample Variance100529.9T
Range719.6M
R-Value0.87
Mean Square Error26191.8T
R-Squared0.76
Significance0.000012
Slope57,936,634
Total Sum of Squares1507948T

Passage Other Stockholder Equity History

2025550.9 M
2024720.5 M
2023705.8 M
2022694.7 M
2021675.3 M
2020475.6 M
2019233 M

About Passage Bio Financial Statements

Passage Bio stakeholders use historical fundamental indicators, such as Passage Bio's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Passage Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Passage Bio's assets and liabilities are reflected in the revenues and expenses on Passage Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Passage Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity720.5 M550.9 M

Currently Active Assets on Macroaxis

When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.07)
Return On Assets
(0.32)
Return On Equity
(0.75)
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.